Video

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

Author(s):

Tina Cascone, MD, PhDSandip Patel, MD

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Ben Levy, MD, and Yan Leyfman, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Related Content
Eric Vallieres, MD, FRCSC, of Swedish Medical Center
June 13th 2024

A Surgeon’s Perspective: How to Optimize Outcomes With Neoadjuvant Chemo/IO in Lung Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Fabrice Barlesi, MD, PhD
June 10th 2024

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

Minesh Mehta, MD
June 4th 2024

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

Lung cancer - stock.adobe.com
June 4th 2024

Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC